Skip to main content
Have a personal or library account? Click to login
Epidemiology, Pathogenesis, and Diagnosis of Cardiac Sarcoidosis Cover

Epidemiology, Pathogenesis, and Diagnosis of Cardiac Sarcoidosis

Open Access
|Mar 2022

References

  1. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007 Nov 22;357(21):2153-65. doi: 10.1056/NEJMra071714
  2. Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac Sarcoidosis. J Am Coll Cardiol. 2016 Jul 26;68(4):411-21. doi: 10.1016/j.jacc.2016.03.605
  3. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014 Jul;11(7):1305-23. doi: 10.1016/j.hrthm.2014.03.043
  4. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015 Feb 17;131(7):624-32. doi: 10.1161/CIRCULATIONAHA.114.011522
  5. Arkema EV, Cozier YC. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med. 2020 Sep;26(5):527-534. doi: 10.1097/MCP.0000000000000715
  6. Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc. 2016 Aug;13(8):1244-52. doi: 10.1513/AnnalsATS.201511-760OC
  7. Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. Chest. 2011 Jan;139(1):144-50. doi: 10.1378/chest.10-0413
  8. Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015 Feb;147(2):438-449. doi: 10.1378/chest.14-1120
  9. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1885-9. doi: 10.1164/ajrccm.164.10.2104046
  10. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008 Feb;31(2):372-9. doi: 10.1183/09031936.00075307
  11. Pizarro C, Goebel A, Dabir D, et al. Cardiovascular magnetic resonance-guided diagnosis of cardiac affection in a Caucasian sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis. 2016 Jan 18;32(4):325-35.
  12. Vignaux O, Dhote R, Duboc D, et al. Detection of myocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. Sep-Oct 2002;26(5):762-7. doi: 10.1097/00004728-200209000-00017
  13. Al-Kindi SG, Oliveira GH. Letter by Al-Kindi and Oliveira regarding article “cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study”. Circulation. 2015 Oct 27;132(17):e211. doi: 10.1161/CIRCULATIONAHA.115.016258
  14. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med. 1997 Nov;156(5):1601-5. doi: 10.1164/ajrccm.156.5.9704069
  15. Ezzie ME, Crouser ED. Considering an infectious etiology of sarcoidosis. Clin Dermatol. May-Jun 2007;25(3):259-66. doi: 10.1016/j.clindermatol.2007.03.003
  16. Barnard J, Rose C, Newman L, et al. Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med. 2005 Mar;47(3):226-34. doi: 10.1097/01.jom.0000155711.88781.91
  17. Hena KM, Murphy S, Zhang Y, Shao Y, Kazeros A, Reibman J. Clinical Evaluation of Sarcoidosis in Community Members with World Trade Center Dust Exposure. Int J Environ Res Public Health. 2019 Apr 10;16(7):1291. doi: 10.3390/ijerph16071291
  18. Izbicki G, Chavko R, Banauch GI, et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest. 2007 May;131(5):1414-23. doi: 10.1378/chest.06-2114
  19. Belperio JA, Shaikh F, Abtin F, et al. Extrapulmonary sarcoidosis with a focus on cardiac, nervous system, and ocular involvement. EClinicalMedicine. 2021 Jun 27;37:100966. doi: 10.1016/j.eclinm.2021.100966
  20. Lagana SM, Parwani AV, Nichols LC. Cardiac sarcoidosis: a pathology-focused review. Arch Pathol Lab Med. 2010 Jul;134(7):1039-46. doi: 10.5858/2009-0274-RA.1
  21. Wahlström J, Katchar K, Wigzell H, Olerup O, Eklund A, Grunewald J. Analysis of intracellular cytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med. 2001 Jan;163(1):115-21. doi: 10.1164/ajrccm.163.1.9906071
  22. Schoppet M, Pankuweit S, Maisch B. Cardiac sarcoidosis: cytokine patterns in the course of the disease. Arch Pathol Lab Med. 2003 Sep;127(9):1207-10. doi: 10.5858/2003-127-1207-CSCPIT
  23. Liu Y, Qiu L, Wang Y, et al. The Circulating Treg/Th17 Cell Ratio Is Correlated with Relapse and Treatment Response in Pulmonary Sarcoidosis Patients after Corticosteroid Withdrawal. PLoS One. 2016 Feb 4;11(2):e0148207. doi: 10.1371/journal.pone.0148207
  24. Ramstein J, Broos CE, Simpson LJ, et al. IFN-γ-Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells. Am J Respir Crit Care Med. 2016 Jun 1;193(11):1281-91. doi: 10.1164/rccm.201507-1499OC
  25. Serei VD, Fyfe B. The Many Faces of Cardiac Sarcoidosis. Am J Clin Pathol. 2020 Feb 8;153(3):294-302. doi: 10.1093/ajcp/aqz169
  26. Bagwan IN, Hooper LVB, Sheppard MN. Cardiac sarcoidosis and sudden death. The heart may look normal or mimic other cardiomyopathies. Virchows Arch. 2011 Jun;458(6):671-8. doi: 10.1007/s00428-010-1003-8
  27. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977 Jul;63(1):86-108. doi: 10.1016/0002-9343(77)90121-8
  28. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009 Nov 17;120(20):1969-77. doi: 10.1161/CIRCULATIONAHA.109.851352
  29. Kurmann R, Mankad SV, Mankad R. Echocardiography in Sarcoidosis. Curr Cardiol Rep. 2018 Sep 26;20(11):118. doi: 10.1007/s11886-018-1065-9
  30. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009 Jan;157(1):9-21. doi: 10.1016/j.ahj.2008.09.009
  31. Gilotra NA, Griffin JM, Pavlovic N, et al. Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review. J Card Fail. 2022 Jan;28(1):113-132. doi: 10.1016/j.cardfail.2021.06.016
  32. Okada DR, Smith J, Derakhshan A, et al. Ventricular Arrhythmias in Cardiac Sarcoidosis. Circulation. 2018 Sep 18;138(12):1253-1264. doi: 10.1161/CIRCULATIONAHA.118.034687
  33. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014 Feb 4;63(4):329-36. doi: 10.1016/j.jacc.2013.09.022
  34. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001 Nov 1;88(9):1006-10. doi: 10.1016/s0002-9149(01)01978-6
  35. Terasaki F, Azuma A, Anzai T, et al. JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis – Digest Version. Circ J. 2019 Oct 25;83(11):2329-2388. doi: 10.1253/circj.CJ-19-0508
  36. Uusimaa P, Ylitalo K, Anttonen O, et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace. 2008 Jun;10(6):760-6. doi: 10.1093/europace/eun110
  37. Rossides M, Kullberg S, Grunewald J, et al. Risk and predictors of heart failure in sarcoidosis in a population-based cohort study from Sweden. Heart. 2021 May 21;heartjnl-2021-319129. doi: 10.1136/heartjnl-2021-319129
  38. Slart RHJ, Glaudemans AWJ, Lancellotti P, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol. 2018 Feb;25(1):298-319. doi: 10.1007/s12350-017-1043-4
  39. Akamatsu K, Ito T, Terasaki F, Hoshiga M. Myocardial findings evaluated by echocardiography in cardiac sarcoidosis: A report of seven cases. J Clin Ultrasound. 2021 Nov;49(9):940-946. doi: 10.1002/jcu.23058
  40. Birnie DH. Cardiac Sarcoidosis. Semin Respir Crit Care Med. 2020 Oct;41(5):626-640. doi: 10.1055/s-0040-1712535
  41. Barssoum K, Altibi AM, Rai D, et al. Speckle tracking echocardiography can predict subclinical myocardial involvement in patients with sarcoidosis: A meta-analysis. Echocardiography. 2020 Dec;37(12):2061-2070. doi: 10.1111/echo.14886
  42. Terasaki F, Yoshinaga K. New guidelines for diagnosis of cardiac sarcoidosis in Japan. Ann Nucl Cardiol. 2017 Aug 10;3(1):42-45. doi: 10.17996/anc.17-00042
  43. Tanada Y, Sato Y, Sawa T, Fujiwara H, Takatsu Y. Serial measurement of high-sensitivity cardiac troponin I and N-terminal proB-type natriuretic peptide in a patient presenting with cardiac sarcoidosis. Intern Med. 2012;51(24):3379-81. doi: 10.2169/internalmedicine.51.8334
  44. Kandolin R, Lehtonen J, Airaksinen J, et al. Usefulness of Cardiac Troponins as Markers of Early Treatment Response in Cardiac Sarcoidosis. Am J Cardiol. 2015 Sep 15;116(6):960-4. doi: 10.1016/j.amjcard.2015.06.021
  45. Kiko T, Yoshihisa A, Kanno Y, et al. A Multiple Biomarker Approach in Patients with Cardiac Sarcoidosis. Int Heart J. 2018 Sep 26;59(5):996-1001. doi: 10.1536/ihj.17-695
  46. Jeudy J, Burke AP, White CS, Kramer GBG, Frazier AA. Cardiac sarcoidosis: the challenge of radiologic-pathologic correlation: from the radiologic pathology archives. Radiographics. May-Jun 2015;35(3):657-79. doi: 10.1148/rg.2015140247
  47. Oyama-Manabe N, Manabe O, Aikawa T, Tsuneta S. The Role of Multimodality Imaging in Cardiac Sarcoidosis. Korean Circ J. 2021 Jul;51(7):561-578. doi: 10.4070/kcj.2021.0104
  48. Kouranos V, Tzelepis GE, Rapti A, et al. Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017 Dec;10(12):1437-1447. doi: 10.1016/j.jcmg.2016.11.019
  49. Blankstein R, Waller AH. Evaluation of Known or Suspected Cardiac Sarcoidosis. Circ Cardiovasc Imaging, 2016 Mar;9(3):e000867. doi: 10.1161/CIRCIMAGING.113.000867
  50. Vita, T., et al., Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis. Circ Cardiovasc Imaging. 2018 Jan;11(1):e007030. doi: 10.1161/CIRCIMAGING.117.007030
  51. Okasha O, Kazmirczak F, Chen KA, Farzaneh-Far A, Shenoy C. Myocardial Involvement in Patients With Histologically Diagnosed Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis of Gross Pathological Images From Autopsy or Cardiac Transplantation Cases. J Am Heart Assoc. 2019 May 21;8(10):e011253. doi: 10.1161/JAHA.118.011253
  52. Zhang J, Li Y, Xu Q, Xu B, Wang H. Cardiac Magnetic Resonance Imaging for Diagnosis of Cardiac Sarcoidosis: A Meta-Analysis. Can Respir J. 2018 Dec 17;2018:7457369. doi: 10.1155/2018/7457369
  53. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017 Apr;10(4):411-420. doi: 10.1016/j.jcmg.2016.05.009
  54. Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC Expert Consensus Document on the Role of 18 F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. J Nucl Med. 2017 Aug;58(8):1341-1353. doi: 10.2967/jnumed.117.196287
  55. Manapragada PP, Andrikopoulou E, Bajaj N, Bhambhvani P. PET Cardiac Imaging (Perfusion, Viability, Sarcoidosis, and Infection). Radiol Clin North Am. 2021 Sep;59(5):835-852. doi: 10.1016/j.rcl.2021.05.009
  56. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004 Dec;45(12):1989-98.
  57. Kumita S, Yoshinaga K, Miyagawa M, et al. Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations. J Nucl Cardiol. 2019 Aug;26(4):1414-1433. doi: 10.1007/s12350-019-01755-3
  58. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012 Feb;53(2):241-8. doi: 10.2967/jnumed.111.090662
  59. Bekki M, Tahara N, Tahara A, et al. Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-naïve cardiac sarcoidosis. J Nucl Cardiol. 2021 Jul 6. doi: 10.1007/s12350-021-02684-w
  60. Coulden RA, Sonnex EP, Abele JT, Crean AM. Utility of FDG PET and Cardiac MRI in Diagnosis and Monitoring of Immunosuppressive Treatment in Cardiac Sarcoidosis. Radiol Cardiothorac Imaging. 2020 Aug 27;2(4):e190140. doi: 10.1148/ryct.2020190140
  61. Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. J Nucl Cardiol. 2017 Apr;24(2):413-424. doi: 10.1007/s12350-016-0490-7
  62. Osborne MT, Hulten EA, Singh A, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014 Feb;21(1):166-74. doi: 10.1007/s12350-013-9828-6
  63. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999 Aug;138(2 Pt 1):299-302. doi: 10.1016/s0002-8703(99)70115-8
  64. Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011 Nov;270(5):461-8. doi: 10.1111/j.1365-2796.2011.02396.x
  65. Ardehali H, Howard DL, Hariri A, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J. 2005 Sep;150(3):459-63. doi: 10.1016/j.ahj.2004.10.006
  66. Ezzeddine FM, Kapa S, Rosenbaum A, et al. Electrogram-guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes. J Cardiovasc Electrophysiol. 2021 Sep;32(9):2486-2495. doi: 10.1111/jce.15191
  67. Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician. 2016 May 15;93(10):840-8
  68. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999 Aug;160(2):736-55. doi: 10.1164/ajrccm.160.2.ats4-99
  69. Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18;31(1):19-27.
  70. Kupari M, Lehtonen J. POINT: Should Isolated Cardiac Sarcoidosis Be Considered a Significant Manifestation of Sarcoidosis? Yes. Chest. 2021 Jul;160(1):36-38. doi: 10.1016/j.chest.2020.12.037
  71. Tezuka D, Terashima M, Kato Y, et al. Clinical characteristics of definite or suspected isolated cardiac sarcoidosis: application of cardiac magnetic resonance imaging and 18F-Fluoro-2-deoxyglucose positron-emission tomography/computerized tomography. J Card Fail. 2015 Apr;21(4):313-22. doi: 10.1016/j.cardfail.2014.12.004
  72. Simonen P, Lehtonen J, Kandolin R, et al. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol. 2015 Nov 15;116(10):1581-5. doi: 10.1016/j.amjcard.2015.08.025
  73. Juneau D, Nery P, Russo J, et al. How common is isolated cardiac sarcoidosis? Extra-cardiac and cardiac findings on clinical examination and whole-body 18 F-fluorodeoxyglucose positron emission tomography. Int J Cardiol. 2018 Feb 15;253:189-193. doi: 10.1016/j.ijcard.2017.09.204
  74. Giudicatti L, Marangou J, Nolan D, Dembo L, Baumwol J, Dwivedi G. The Utility of Whole Body 18F-FDG PET-CT in Diagnosing Isolated Cardiac Sarcoidosis: The Western Australian Cardiac Sarcoid Study. Heart Lung Circ. 2020 Jan;29(1):e1-e6. doi: 10.1016/j.hlc.2019.07.007
  75. Kawai H, Sarai M, Kato Y, et al. Diagnosis of isolated cardiac sarcoidosis based on new guidelines. ESC Heart Fail. 2020 Oct;7(5):2662-2671. doi: 10.1002/ehf2.12853
  76. Sperry BW, Oldan J, Hachamovitch R, Tamarappoo BK. Insights into biopsy-proven cardiac sarcoidosis in patients with heart failure. J Heart Lung Transplant. 2016 Mar;35(3):392-393. doi: 10.1016/j.healun.2015.12.005
  77. Chazal T, Varnous S, Guihaire J, et al. Sarcoidosis diagnosed on granulomas in the explanted heart after transplantation: Results of a French nationwide study. Int J Cardiol. 2020 May 15;307:94-100. doi: 10.1016/j.ijcard.2019.12.066
  78. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2013 Nov;18(6):733-46. doi: 10.1007/s10741-012-9358-3
  79. Bharati S, Surawicz B, Vidaillet HJ Jr, Lev M. Familial congenital sinus rhythm anomalies: clinical and pathological correlations. Pacing Clin Electrophysiol. 1992 Nov;15(11 Pt 1):1720-9. doi: 10.1111/j.1540-8159.1992.tb02960.x
  80. Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013 May;6(5):587-96. doi: 10.1016/j.jcmg.2012.09.018
  81. Yafasova A, Fosbøl EL, Schou M, et al. Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. J Am Coll Cardiol. 2020 Aug 18;76(7):767-777. doi: 10.1016/j.jacc.2020.06.038
DOI: https://doi.org/10.14797/mdcvj.1057 | Journal eISSN: 1947-6108
Language: English
Page range: 78 - 93
Submitted on: Nov 1, 2021
Accepted on: Jan 7, 2022
Published on: Mar 14, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2022 Sheetal V. Mathai, Snehal Patel, Ulrich P. Jorde, Yogita Rochlani, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.